mitomycin + gemcitabine

The combination of mitomycin C (MMC) and gemcitabine (GC) is primarily used in the treatment of non-muscle-invasive bladder cancer (NMIBC), particularly in patients who have experienced recurrence after previous intravesical therapy. This combination has shown promising results in providing durable recurrence-free survival for patients who are not candidates for or refuse cystectomy (surgical removal of the bladder)[1][3]. ## Mechanism of Action Mitomycin C and gemcitabine are both cytotoxic agents that work by inhibiting DNA synthesis in cancer cells[4]. When administered intravesically (directly into the bladder), they target bladder cancer cells while minimizing systemic exposure and side effects. The combination therapy typically involves sequential instillation of these drugs weekly for 6-8 weeks[1]. Studies have shown that this combination can offer a median disease-free survival of 15.2 months, with some patients experiencing no evidence of disease at follow-up periods extending beyond 22 months[1]. ## Clinical Applications The primary application for mitomycin + gemcitabine is in recurrent non-muscle-invasive bladder cancer, particularly in high-risk cases (high-grade or carcinoma in situ) and intermediate-risk cases (multifocal or recurrent low-grade)[1]. This combination is especially valuable for patients who: - Have failed previous intravesical therapy (particularly BCG) - Are not candidates for cystectomy - Refuse cystectomy as a treatment option The combination has also been studied in advanced pancreatic cancer, where it has shown favorable results compared to single-agent chemotherapy, with a median overall survival of 7.25 months[2]. ## Side Effects Common side effects of the mitomycin + gemcitabine combination include: - Thrombocytopenia (low platelet count) - Bladder irritation symptoms (dysuria, frequency, urgency) - Cystitis - Hematuria (blood in urine) - Fatigue - Dermatitis - Nausea More serious but less common side effects may include pneumonitis, hemolytic uremic syndrome, and bladder contracture[2][4]. ## Efficacy In studies of patients with recurrent NMIBC, the combination therapy has demonstrated: - Median disease-free survival of 15.2 months - 37% of patients with no evidence of disease at follow-up (median follow-up of 22.1 months) - Tumor growth control in 62% of patients (in pancreatic cancer studies) - Objective response rate of 29% (in pancreatic cancer studies)[1][2] This combination represents an important treatment option for patients with recurrent bladder cancer who have limited alternatives, offering the potential for meaningful disease control and improved quality of life.

Other names

mitomycin C + gemcitabineMMC + GC